Neurogt Inc.
Durham, NC
- UEI
- NQHRNCAD21P3
- CAGE
- 89H58
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 5 Silverton Ct, Durham, NC 27713, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Neurogt Inc.
Neurogt Inc. is a biotechnology company based in Durham, North Carolina, registered as a minority-owned, woman-owned small disadvantaged business. Founded by Dr. Haiyan Fu, an associate professor from the University of North Carolina at Chapel Hill's Gene Therapy Center, the company focuses on developing and commercializing gene therapy products for rare neurogenetic diseases. Specifically, Neurogt Inc. specializes in developing adeno-associated virus (AAV) gene therapy solutions targeting lysosomal storage diseases (LSDs), with a particular emphasis on neurological disorders that currently lack effective treatments.
The company has received multiple federal grants from key research agencies, including the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Allergy and Infectious Diseases. Its grant-funded projects have concentrated on developing innovative AAV9 gene replacement therapies for specific rare genetic conditions such as Mucopolysaccharidosis (MPS) types I, IIIB, and IIIC. These projects involve advanced research into gene therapy vectors, including self-complementary AAV vectors with codon-optimized genetic constructs designed to enhance protein expression and potentially enable bystander effects. Neurogt Inc. has also been working on complementary technologies, such as developing an "Antibody Cleaver" (ABC) protein to address challenges with pre-existing antibodies that can limit gene therapy effectiveness. The company's research aims to create therapeutic strategies that can cross the blood-brain barrier and provide functional correction for severe neurological disorders, with a particular focus on developing treatments for conditions that currently have no effective interventions.
Quick answers
What is Neurogt Inc.'s UEI?
Neurogt Inc.'s Unique Entity ID (UEI) in SAM.gov is NQHRNCAD21P3.
What is Neurogt Inc.'s CAGE code?
Neurogt Inc.'s CAGE code is 89H58.
What is Neurogt Inc.'s primary NAICS code?
Neurogt Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Neurogt Inc. located?
Neurogt Inc.'s physical address in SAM.gov is 5 Silverton Ct, Durham, NC 27713, USA.
Is Neurogt Inc. registered in SAM.gov?
Yes. Neurogt Inc.'s SAM.gov registration is active through April 16, 2027.
What is Neurogt Inc.'s most recent federal award?
Neurogt Inc.'s most recent federal grant award is Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS i - project summary the goal of this phase II sbir project… (R44NS143501), from National Institute of Neurological Disorders and Stroke, on September 16, 2025.
On GovTribe
See Neurogt Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors